Rebiopsy Enhances Survival with Afatinib Vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan

Overview

Journal Curr Oncol

Publisher MDPI

Date 2025 Jan 24

PMID 39851952

Authors

Jerry Shu-Hung Kuo

Cheng-Yu Chang

Shih-Chieh Chang

Yu-Feng Wei

Chung-Yu Chen

Affiliations

Soon will be listed here.

Abstract

Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatinib and Osimertinib in NSCLC patients with EGFR 19del and no brain metastases at diagnosis.

Methods: The primary endpoints were time on treatment (ToT) and overall survival (OS). Survival analyses were performed for three groups: Afatinib followed by Osimertinib, Afatinib followed by other therapies, and Osimertinib (alone or followed by other therapies). Rebiopsy practices, including T790M mutation detection, were also analyzed in patients with disease progression on Afatinib.

Results: Among 97 Afatinib-treated and 60 Osimertinib-treated patients, Osimertinib showed a significantly longer ToT (23.3 vs. 16.5 months; = 0.007). Median OS was numerically higher for Afatinib with sequential Osimertinib (40.5 vs. 34.6 months for Osimertinib; = 0.473). Osimertinib demonstrated advantages, with fewer brain metastases upon progression and fewer adverse effects. In the Afatinib group, 64% of patients with disease progression underwent rebiopsy, with 39% testing positive for T790M mutation and subsequently receiving Osimertinib. Rebiopsy was most frequently performed on the lung parenchyma using non-surgical methods.

Conclusions: In this real-world study, Osimertinib achieved a significantly longer ToT compared to Afatinib in NSCLC patients with EGFR 19del and no brain metastases. The sequential use of Afatinib followed by Osimertinib showed a trend toward improved OS, highlighting the importance of rebiopsy for identifying T790M mutations to guide subsequent therapy.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Chen P, Wang C, Hsu C, Chen C . Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Front Pharmacol. 2021; 12:720687. PMC: 8382571. DOI: 10.3389/fphar.2021.720687. View

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

Ballard P, Yates J, Yang Z, Kim D, Yang J, Cantarini M . Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016; 22(20):5130-5140. DOI: 10.1158/1078-0432.CCR-16-0399. View

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

Huang Y, Hsu K, Tseng J, Yang T, Chen K, Su K . The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. Target Oncol. 2022; 17(3):295-306. PMC: 9633524. DOI: 10.1007/s11523-022-00878-x. View

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

Oxnard G, Arcila M, Sima C, Riely G, Chmielecki J, Kris M . Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2010; 17(6):1616-22. PMC: 3060283. DOI: 10.1158/1078-0432.CCR-10-2692. View

Molife C, Winfree K, Bailey H, Dyachkova Y, Forshaw C, Kim S . Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study. Adv Ther. 2023; 40(7):3135-3168. PMC: 10204685. DOI: 10.1007/s12325-023-02530-0. View

10.

Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A . First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist. 2022; 27(2):87-e115. PMC: 9714585. DOI: 10.1002/onco.13951. View

11.

Hsu J, Wei C, Yang S . Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. BMJ Open. 2019; 9(3):e022293. PMC: 6429989. DOI: 10.1136/bmjopen-2018-022293. View

12.

Lee K, Kim Y, Jung H, Lee S, Ahn J, Ahn M . Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer. 2019; 130:87-92. DOI: 10.1016/j.lungcan.2019.01.012. View

13.

Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B . Osimertinib afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023; 15(11):6115-6125. PMC: 10713299. DOI: 10.21037/jtd-23-686. View

14.

Kuo C, Su P, Wei Y, Ko J, Tseng J, Su J . T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study). Am J Cancer Res. 2023; 13(7):3100-3112. PMC: 10408489. View

15.

Park K, Tan E, OByrne K, Zhang L, Boyer M, Mok T . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X. View

16.

Wang C, Zhao K, Hu S, Dong W, Gong Y, Xie C . Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis. Oncologist. 2023; 28(6):e397-e405. PMC: 10243768. DOI: 10.1093/oncolo/oyad111. View

17.

Huang Y, Tseng J, Hsu K, Chen K, Su K, Yu S . The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Sci Rep. 2021; 11(1):12084. PMC: 8187359. DOI: 10.1038/s41598-021-91657-7. View

18.

Reungwetwattana T, Nakagawa K, Cho B, Cobo M, Cho E, Bertolini A . CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; :JCO2018783118. DOI: 10.1200/JCO.2018.78.3118. View

19.

Molife C, Cho J, Lapthorn J, Kang M, Dyachkova Y, Kim S . Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea. Drugs Real World Outcomes. 2022; 10(1):131-143. PMC: 9715413. DOI: 10.1007/s40801-022-00344-0. View

20.

Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-7. PMC: 3630270. DOI: 10.1158/1078-0432.CCR-12-2246. View